Valuation: AstraZeneca PLC

Market Cap 264B 228B 213B 195B 370B 25,158B 374B 2,508B 983B 12,522B 990B 969B 41,484B P/E 2026 *
21.8x
P/E 2027 * 19x
Enterprise Value 284B 246B 229B 210B 398B 27,071B 403B 2,699B 1,057B 13,474B 1,066B 1,042B 44,638B EV / Sales 2026 *
4.48x
EV / Sales 2027 * 4.13x
Free-Float
96.63%
Yield 2026 *
1.96%
Yield 2027 * 2.07%
1 day-0.34%
1 week-1.36%
1 month-9.21%
3 months-6.11%
6 months-1.33%
Current year-4.46%
1 week 1,616
Extreme 1616
1,699
1 month 1,587
Extreme 1587
1,880.5
Current year 1,587
Extreme 1587
1,925.5
1 year 1,365
Extreme 1365
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 960.3
Extreme 960.3
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.36% - - 264B
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
+0.69%+5.19%+47.66%+6.14% 133B
Average -1.09%-0.60%+29.79%+41.67% 365.4B
Weighted average by Cap. -0.91%-1.86%+38.40%+73.97%

Financials

2026 *2027 *
Net sales 63.28B 54.79B 51.06B 46.88B 88.67B 6,036B 89.79B 602B 236B 3,004B 238B 232B 9,954B 66.85B 57.89B 53.94B 49.53B 93.67B 6,377B 94.86B 636B 249B 3,174B 251B 246B 10,516B
Net income 12.09B 10.46B 9.75B 8.95B 16.93B 1,153B 17.15B 115B 45.03B 574B 45.38B 44.39B 1,901B 13.71B 11.87B 11.06B 10.16B 19.21B 1,308B 19.45B 130B 51.08B 651B 51.49B 50.36B 2,157B
Net Debt 20.05B 17.36B 16.18B 14.86B 28.1B 1,913B 28.45B 191B 74.71B 952B 75.31B 73.66B 3,154B 12.56B 10.88B 10.14B 9.31B 17.6B 1,198B 17.82B 119B 46.8B 596B 47.17B 46.14B 1,976B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
31/07/26 SEK 1,627.50 -0.34% 417,185
30/07/26 SEK 1,633.00 -3.57% 756,672
29/07/26 SEK 1,693.50 +1.35% 595,230
28/07/26 SEK 1,671.00 -0.33% 593,299
27/07/26 SEK 1,676.50 +1.61% 634,985
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
170.04USD
Average target price
212.34USD
Spread / Average Target
+24.87%

Quarterly revenue - Rate of surprise